Growth hormone and oxandrolone in burned children

Nigel Tapiwa Mabvuure, Alexis N. Thomas, Linda E. Sousse

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Abstract

    Children with large burns exhibit a hypermetabolic state, often resulting in bone loss and growth velocity impairment. The hypothesis that anabolic drugs may counteract bone loss is based on observations made from using these drugs in conditions of short stature such as Turner's syndrome. Two anabolic agents that have been used successfully in these settings are exogenous human growth hormone and oxandrolone, a testosterone analogue. In this chapter, we review the literature that demonstrates that the administration of these two drugs in burned children is both safe and efficacious in improving post-burn bone health outcomes. The systemic action of these anabolic agents beyond the bone metabolic system has also been explored in the clinical trials described. However, only bone-related markers are discussed in detail in this chapter.

    Original languageEnglish (US)
    Title of host publicationBone Drugs in Pediatrics
    Subtitle of host publicationEfficacy and Challenges
    PublisherSpringer US
    Pages135-152
    Number of pages18
    ISBN (Electronic)9781489974365
    ISBN (Print)1489974350, 9781489974358
    DOIs
    StatePublished - Feb 1 2014

    ASJC Scopus subject areas

    • Medicine(all)

    Fingerprint Dive into the research topics of 'Growth hormone and oxandrolone in burned children'. Together they form a unique fingerprint.

  • Cite this

    Mabvuure, N. T., Thomas, A. N., & Sousse, L. E. (2014). Growth hormone and oxandrolone in burned children. In Bone Drugs in Pediatrics: Efficacy and Challenges (pp. 135-152). Springer US. https://doi.org/10.1007/978-1-4899-7436-5_9